E4-YBONE Study: Estetrol and Bone Metabolism in Young Women

Multicenter Study on the Effects of an Estetrol-Containing Low-Dose Combined Oral Contraceptive on Bone Metabolism in Young Women - E4-YBONE Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000059653

Enrollment

Registered

2025-11-15

Start date

2025-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dysmenorrhea

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients diagnosed with dysmenorrhea Female patients aged 15 to 22 years who are at least 3 years after menarche Patients who can provide written informed consent

Exclusion criteria

Exclusion criteria: Patients with a history of treatment with low-dose estrogen-progestin preparations for dysmenorrhea Patients with a history of treatment with hormonal agents other than LEP preparations Patients with a history of treatment with bone metabolism drugs Patients with contraindications to estetrol-containing low-dose LEP preparations

Design outcomes

Primary

Measure	Time frame
Longitudinal change in bone mineral density and bone quality (DXA)	—

Secondary

Measure	Time frame
Changes in bone metabolic markers (Tracp-5b, P1NP, IGF-I, etc.), and occurrence of adverse events	—

Countries

Japan

Contacts

Public ContactSHIN SAITO

Yokohama City University Medical Center Gynecology

saito_s@yokohama-cu.ac.jp0452615656

Outcome results